Skip to main content

Table 1 Clinical and pathological characteristics of patient cohorts used to assess prognostic significance of EMAT subtypes

From: Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature

Factor METABRIC (n = 562)
No. (%)
GSE11121 (n = 200)
No. (%)
NKI295 (n = 151)
No. (%)
Age, years
 < 50 20.8 23.2 84.1
 > 50 78.8 76.8 15.9
 Unknown 0.4 100  
Tumor size, cm
 < 2 39.5 49.5 54.3
 2–5 57.7 49 45.7
 > 5 2.3 1.5  
 Unknown 0.5 0 0
Tumor grade
 Low 8.5 14.5 22.5
 Intermediate 42.3 68 30.5
 High 42.3 17.5 47.0
 Unknown 6.8 0 0
ER
 Negative 17.3 23.2 27.8
 Positive 78.8 76.8 72.2
 Unknown 3.9 0 0
PR
 Negative 43.8 41.8  
 Positive 56.2 58.2  
 Unknown 0 0 100
HER2
 Negative 80.2 89.0  
 Positive 19.4 0.11  
 Unknown 0.4 0 100
Adjuvant therapy
 Chemotherapy 7.1 N/A 4.0
 Hormonal therapy 47.9 N/A 4.0
 Radiation therapy 54.4 N/A 40.4
PAM50 status
 Luminal A 44.1 27 31.8
 Luminal B 19.9 23.5 25.2
 HER2 7.5 12.5 16.6
 Basal-like 15.3 17.5 18.5
 Normal-like 13 18 7.9
EMAT status
 EMAT1 19.4 22.5 17.2
 EMAT2 45.7 31 35.1
 EMAT3 26 29.5 27.8
 EMAT4 8.9 17 19.9
  1. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor